

Shankar Siva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8540870/publications.pdf>

Version: 2024-02-01

182
papers

6,536
citations

66234

42
h-index

79541

73
g-index

184
all docs

184
docs citations

184
times ranked

7010
citing authors

#	ARTICLE	IF	CITATIONS
1	International Multi-institutional Patterns of Contouring Practice and Clinical Target Volume Recommendations for Stereotactic Body Radiation Therapy for Non-Spine Bone Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 351-360.	0.4	8
2	Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial. <i>European Urology</i> , 2022, 81, 253-262.	0.9	34
3	Substituting SABR for systemic therapy in oligometastatic renal cell carcinoma – buying time or time to change?. <i>Nature Reviews Urology</i> , 2022, 19, 197-198.	1.9	3
4	Systematic Review of Single-Fraction Stereotactic Body Radiation Therapy for Early Stage Non-Small-Cell Lung Cancer and Lung Oligometastases: How to Stop Worrying and Love One and Done. <i>Cancers</i> , 2022, 14, 790.	1.7	22
5	Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 166.e9-166.e13.	0.8	17
6	Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma – The RAPPORT Trial. <i>European Urology</i> , 2022, 81, 364-372.	0.9	70
7	Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions. <i>Biomedicines</i> , 2022, 10, 821.	1.4	5
8	Cost Effectiveness Analysis of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) for Early Stage Renal Cell Carcinoma (RCC). <i>Clinical Genitourinary Cancer</i> , 2022, 20, e353-e361.	0.9	3
9	Pre-emptive or reactive? PROMPT spinal screening in metastatic castration-resistant prostate cancer. <i>Lancet Oncology</i> , The, 2022, 23, 443-444.	5.1	0
10	A Patient-Level Data Meta-analysis of the Abscopal Effect. <i>Advances in Radiation Oncology</i> , 2022, 7, 100909.	0.6	20
11	Utility of Biology-Guided Radiotherapy to De Novo Metastases Diagnosed During Staging of High-Risk Biopsy-Proven Prostate Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 854589.	1.3	5
12	Quantitative assessment of ventilation-perfusion relationships with gallium-68 positron emission tomography/computed tomography imaging in lung cancer patients. <i>Physics and Imaging in Radiation Oncology</i> , 2022, 22, 8-12.	1.2	4
13	Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial. <i>Radiotherapy and Oncology</i> , 2022, 172, 1-9.	0.3	4
14	Cost-Effectiveness of Single Versus Multifraction SABR for Pulmonary Oligometastases: The SAFRON II Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 968-976.	0.4	4
15	Health related quality of life outcomes following stereotactic body radiotherapy in patients with oligo-metastatic disease: A systematic review and individual patient data meta-analysis. <i>Radiotherapy and Oncology</i> , 2022, 173, 163-169.	0.3	6
16	Impact of Medical Operability and Total Metastatic Ablation on Outcomes After SABR for Oligometastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 862-870.	0.4	5
17	Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 2957-2995.	0.8	97
18	Assessing organ at risk position variation and its impact on delivered dose in kidney SABR. <i>Radiation Oncology</i> , 2022, 17, .	1.2	0

#	ARTICLE	IF	CITATIONS
19	The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma. <i>European Urology</i> , 2022, 82, 613-622.	0.9	27
20	Practical considerations of single-fraction stereotactic ablative radiotherapy to the lung. <i>Lung Cancer</i> , 2022, 170, 185-193.	0.9	4
21	Safety, Efficacy, and Patterns of Failure After Single-Fraction Stereotactic Body Radiation Therapy (SBRT) for Oligometastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 756-763.	0.4	17
22	Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma. <i>BJU International</i> , 2021, 127, 703-711.	1.3	20
23	Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer. <i>JAMA Oncology</i> , 2021, 7, 92.	3.4	114
24	Radiation is not the Ideal Solution. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 7-8.	0.4	1
25	A systematic review and meta-analysis of the prognostic value of radiomics based models in non-small cell lung cancer treated with curative radiotherapy. <i>Radiotherapy and Oncology</i> , 2021, 155, 188-203.	0.3	37
26	Reply to Francesco Montorsi, Alessandro Larcher, and Umberto Capitanio's Letter to the Editor re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Eur Urol Focus</i> . 2019 Jun 24. pii: S2405-4569(19)30157-9. https://doi.org/10.1016/j.euf.2019.06.002 . [Epub ahead of print]. <i>European Urology Focus</i> , 2021, 7, 404-405.	1.6	3
27	Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the "TOAST" database. <i>Radiation Oncology</i> , 2021, 16, 4.	1.2	20
28	An International Expert Survey on the Indications and Practice of Radical Thoracic Reirradiation for Non-Small Cell Lung Cancer. <i>Advances in Radiation Oncology</i> , 2021, 6, 100653.	0.6	11
29	The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases. <i>European Urology Focus</i> , 2021, 7, 241-244.	1.6	20
30	On the reduction of aperture complexity in kidney SABR. <i>Journal of Applied Clinical Medical Physics</i> , 2021, 22, 71-81.	0.8	5
31	Automated assessment of functional lung imaging with 68Ga-ventilation/perfusion PET/CT using iterative histogram analysis. <i>EJNMMI Physics</i> , 2021, 8, 23.	1.3	4
32	A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol. <i>Contemporary Clinical Trials Communications</i> , 2021, 21, 100703.	0.5	6
33	Trend in Stereotactic Radiation Therapy Use for Management of Bone and Brain Metastases in Patients with Renal Cell Carcinoma in Australia. <i>Oncologist</i> , 2021, 26, e1288-e1289.	1.9	1
34	A Deep Learning Model to Automate Skeletal Muscle Area Measurement on Computed Tomography Images. <i>Frontiers in Oncology</i> , 2021, 11, 580806.	1.3	22
35	A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2766-2778.	1.3	9
36	Functional and patient-reported changes in swallowing and voice after combined chemotherapy and radiotherapy for limited-stage small-cell lung cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2021, 65, 786-795.	0.9	1

#	ARTICLE	IF	CITATIONS
37	Nodal metabolic tumour volume on baseline 18 Fâ€FDG PET/CT and overall survival in stage II and III NSCLC patients undergoing curativeâ€ntent chemoradiotherapy/radiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2021, 65, 748-754.	0.9	1
38	Lifetime Health and Economic Outcomes of Active Surveillance, Radical Prostatectomy, and Radiotherapy for Favorable-Risk Localized Prostate Cancer. <i>Value in Health</i> , 2021, 24, 1737-1745.	0.1	4
39	Local ablative therapies in oligometastatic NSCLC-upfront or outback?â€”a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3446-3456.	1.3	7
40	Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1023-1033.	5.1	183
41	Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer. <i>Radiation Oncology</i> , 2021, 16, 142.	1.2	8
42	Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II). <i>JAMA Oncology</i> , 2021, 7, 1476.	3.4	50
43	Trends in Diagnosis and Treatment of Metastatic Cancer in the United States. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 572-579.	0.6	15
44	Predicting muscle loss during lung cancer treatment (PREDICT): protocol for a mixed methods prospective study. <i>BMJ Open</i> , 2021, 11, e051665.	0.8	0
45	Reducing the impact on renal function of kidney SABR through management of respiratory motion. <i>Physica Medica</i> , 2021, 89, 72-79.	0.4	3
46	Continued versus Interrupted Targeted Therapy during Metastasis-Directed Stereotactic Radiotherapy: A Retrospective Multi-Center Safety and Efficacy Analysis. <i>Cancers</i> , 2021, 13, 4780.	1.7	8
47	Role of Imaging in Renal Cell Carcinoma: A Multidisciplinary Perspective. <i>Radiographics</i> , 2021, 41, 1387-1407.	1.4	30
48	The Epidemiology of Lung Metastases. <i>Frontiers in Medicine</i> , 2021, 8, 723396.	1.2	17
49	Stereotactic Radiotherapy for Oligoprogressive Disease: A New Frontier in Kidney Cancer. <i>European Urology</i> , 2021, 80, 701-702.	0.9	1
50	Everything But the Kitchen Sink: Comprehensive Nodal Irradiation with Androgen Deprivation in OLIGOPELVIS. <i>European Urology</i> , 2021, 80, 415-416.	0.9	0
51	Surgery versus SABR for early-stage lung cancerâ€”time to call it a draw?. <i>Lancet Oncology</i> , The, 2021, 22, 1355-1357.	5.1	5
52	Radiation Therapy for Renal Cell Carcinoma. <i>Practical Guides in Radiation Oncology</i> , 2021, , 301-312.	0.0	0
53	Inflammation and oxidatively induced DNA damage: A synergy leading to cancer development. , 2021, , 131-147.		1
54	SABR in oligometastatic breast cancer: Current status and future directions. <i>Breast</i> , 2021, 60, 223-229.	0.9	6

#	ARTICLE	IF	CITATIONS
55	Novel agents for metastatic hormone-sensitive prostate cancer – a practice guide for urologists. BJU International, 2020, 125, 342-345.	1.3	6
56	Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis. European Urology, 2020, 77, 365-372.	0.9	116
57	Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial. Breast, 2020, 49, 55-62.	0.9	49
58	Lung Cancer in Australia. Journal of Thoracic Oncology, 2020, 15, 1809-1814.	0.5	13
59	Dose matters for stereotactic body radiotherapy for early stage non-small cell lung cancer. Annals of Translational Medicine, 2020, 8, 1197-1197.	0.7	1
60	The challenge of planning vertebral body SBRT: Optimizing target volume coverage. Medical Dosimetry, 2020, 45, 302-307.	0.4	7
61	Adverse respiratory outcomes following conventional long-course radiotherapy for non-small cell lung cancer in patients with pre-existing pulmonary fibrosis: A comparative retrospective study. Journal of Medical Imaging and Radiation Oncology, 2020, 64, 546-555.	0.9	4
62	Single-Fraction Stereotactic Body Radiation Therapy: A Paradigm During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond?. Advances in Radiation Oncology, 2020, 5, 761-773.	0.6	28
63	Monitoring DNA Damage and Repair in Peripheral Blood Mononuclear Cells of Lung Cancer Radiotherapy Patients. Cancers, 2020, 12, 2517.	1.7	8
64	Stereotactic Ablative Radiotherapy for $\geq T1b$ Primary Renal Cell Carcinoma: A Report From the International Radiosurgery Oncology Consortium for Kidney (IROCK). International Journal of Radiation Oncology Biology Physics, 2020, 108, 941-949.	0.4	48
65	Credentialing of vertebral stereotactic ablative body radiotherapy in a multi-centre trial. Physica Medica, 2020, 72, 16-21.	0.4	5
66	Real-Time Image Guided Ablative Prostate Cancer Radiation Therapy: Results From the TROG 15.01 SPARK Trial. International Journal of Radiation Oncology Biology Physics, 2020, 107, 530-538.	0.4	33
67	Single-fraction stereotactic ablative body radiotherapy for sternal metastases in oligometastatic breast cancer: Technique and single institution experience. Journal of Medical Imaging and Radiation Oncology, 2020, 64, 580-585.	0.9	4
68	Stereotactic Body Radiation Therapy for Nonspine Bone Metastases: International Practice Patterns to Guide Treatment Planning. Practical Radiation Oncology, 2020, 10, e452-e460.	1.1	24
69	Independent review of 4DCT scans used for SABR treatment planning. Journal of Applied Clinical Medical Physics, 2020, 21, 62-67.	0.8	11
70	Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer. Nature Reviews Urology, 2020, 17, 107-118.	1.9	41
71	Single-arm prospective interventional study assessing feasibility of using gallium-68 ventilation and perfusion PET/CT to avoid functional lung in patients with stage III non-small cell lung cancer. BMJ Open, 2020, 10, e042465.	0.8	15
72	What ^{18}F -FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non-Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria?. Journal of Nuclear Medicine, 2019, 60, 328-334.	2.8	24

#	ARTICLE	IF	CITATIONS
73	Intratumoural renal cell carcinoma haemorrhage following stereotactic radiotherapy: a case report. <i>BMC Cancer</i> , 2019, 19, 671.	1.1	5
74	Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma?. <i>Clinical and Translational Radiation Oncology</i> , 2019, 18, 104-112.	0.9	30
75	Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. <i>European Urology</i> , 2019, 76, 732-739.	0.9	99
76	The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>European Urology Focus</i> , 2019, 5, 958-969.	1.6	86
77	Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1219.	1.3	27
78	NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy. <i>Radiation Oncology</i> , 2019, 14, 164.	1.2	12
79	Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. <i>European Urology Oncology</i> , 2019, 2, 515-523.	2.6	97
80	Oligometastatic prostate cancer: The game is afoot. <i>Cancer Treatment Reviews</i> , 2019, 73, 84-90.	3.4	41
81	PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1869-1877.	3.3	19
82	The Abscopal Effect of Stereotactic Radiotherapy and Immunotherapy: Fool's Gold or El Dorado?. <i>Clinical Oncology</i> , 2019, 31, 432-443.	0.6	48
83	Single Fraction SBRT for Early Stage Lung Cancer—Less is More?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 1085-1087.	0.4	9
84	Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer. <i>Current Oncology Reports</i> , 2019, 21, 43.	1.8	9
85	Radiotherapy toxicity. <i>Nature Reviews Disease Primers</i> , 2019, 5, 13.	18.1	434
86	TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adjuvant Androgen deprivation: NINJA study protocol. <i>BMJ Open</i> , 2019, 9, e030731.	0.8	18
87	Systematic endobronchial ultrasound-guided transbronchial needle aspiration improves radiotherapy planning in non-small cell lung cancer. <i>ERJ Open Research</i> , 2019, 5, 00004-2019.	1.1	13
88	Radiation Therapy Modulates DNA Repair Efficiency in Peripheral Blood Mononuclear Cells of Patients With Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 521-531.	0.4	11
89	PET/CT Lung Ventilation and Perfusion Scanning using Galligas and Gallium-68-MAA. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 71-81.	2.5	47
90	Radiotherapy and immunotherapy: a synergistic effect in cancer care. <i>Medical Journal of Australia</i> , 2019, 210, 47-53.	0.8	53

#	ARTICLE	IF	CITATIONS
91	Stereotactic Radiotherapy as a Treatment Option for Renal Tumors in the Solitary Kidney: A Multicenter Analysis from the IROCK. <i>Journal of Urology</i> , 2019, 201, 1097-1104.	0.2	24
92	Stereotactic body radiotherapy for oligometastatic renal cell carcinoma—“are we ready to roll?”. <i>Annals of Translational Medicine</i> , 2019, 7, S180-S180.	0.7	1
93	SABR-COMET: a new paradigm of care lights up the twilight of metastatic disease. <i>Annals of Translational Medicine</i> , 2019, 7, 615-615.	0.7	4
94	Progress in Radiotherapy for Regional and Oligometastatic Disease in 2017. <i>Journal of Thoracic Oncology</i> , 2018, 13, 488-496.	0.5	10
95	Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). <i>Cancer</i> , 2018, 124, 934-942.	2.0	125
96	The great debate flashes: surgery versus stereotactic body radiotherapy as the primary treatment of early-stage lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 295-305.	0.6	11
97	Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of 68Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 625-631.	2.8	62
98	Oligometastatic Renal Cell Carcinoma With Sarcomatoid Differentiation Demonstrating Variable Imaging Phenotypes on 68Ga-PSMA and 18F-FDG PET/CT: A Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 1-5.	0.9	12
99	Single Fraction Stereotactic Ablative Body Radiotherapy for Oligometastasis: Outcomes from 132 Consecutive Patients. <i>Clinical Oncology</i> , 2018, 30, 178-184.	0.6	18
100	TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTERACK II. <i>BMC Cancer</i> , 2018, 18, 1030.	1.1	50
101	Prostate specific membrane antigen: the role in salvage lymph node dissection and radio-ligand therapy. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2018, 70, 450-461.	3.9	5
102	Assessing the Clinical Utility of Computed Tomography-Based Radiomics. <i>Oncologist</i> , 2018, 23, 747-749.	1.9	1
103	Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. <i>European Urology</i> , 2018, 74, 455-462.	0.9	250
104	Stereotactic Body Radiotherapy for Primary Prostate Cancer. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381878963.	0.8	16
105	Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma. <i>PLoS ONE</i> , 2018, 13, e0202387.	1.1	15
106	Functional lung imaging in radiation therapy for lung cancer: A systematic review and meta-analysis. <i>Radiotherapy and Oncology</i> , 2018, 129, 196-208.	0.3	53
107	Utility of ⁶⁸ Ga prostate specific membrane antigen “ positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2017, 61, 372-378.	0.9	83
108	Stereotactic Ablative Body Radiotherapy for the Treatment of Spinal Oligometastases. <i>Clinical Oncology</i> , 2017, 29, e119-e125.	0.6	33

#	ARTICLE	IF	CITATIONS
109	Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial. <i>BJU International</i> , 2017, 120, 623-630.	1.3	85
110	Stereotactic Ablative Body Radiotherapy for Lung Metastases: Where is the Evidence and What are We Doing With It?. <i>Seminars in Radiation Oncology</i> , 2017, 27, 229-239.	1.0	26
111	Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. <i>Nature Reviews Urology</i> , 2017, 14, 549-563.	1.9	88
112	Stereotactic Body Radiotherapy. <i>Medical Radiology</i> , 2017, , 323-395.	0.0	0
113	Re: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer. <i>European Urology</i> , 2017, 72, 320.	0.9	1
114	Glut-1 expression in small cervical biopsies is prognostic in cervical cancers treated with chemoradiation. <i>Clinical and Translational Radiation Oncology</i> , 2017, 2, 53-58.	0.9	8
115	⁶⁸ Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends. <i>Prostate International</i> , 2017, 5, 125-129.	1.2	36
116	The Prickly Predicament of Pursuing Pulmonary Polymetastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 764-765.	0.4	7
117	Re: Declan G. Murphy, Christopher J. Sweeney, Bertrand Tombal. "Gotta Catch 'em All" or Do We? Pokemet Approach to Metastatic Prostate Cancer. <i>Eur Urol</i> 2017;72:1-3. <i>European Urology</i> , 2017, 72, e66-e67.	0.9	2
118	Prostate-Specific Membrane Antigen PET Before Aggressive Local Therapy to the Sternum. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 494-495.	0.4	0
119	Automatic delineation of functional lung volumes with ⁶⁸ Ga-ventilation/perfusion PET/CT. <i>EJNMMI Research</i> , 2017, 7, 82.	1.1	19
120	Stereotactic body radiotherapy for primary renal cell carcinoma and adrenal metastases. <i>Chinese Clinical Oncology</i> , 2017, 6, S17-S17.	0.4	16
121	Lung cancer radiation therapy in Australia and New Zealand: Patterns of practice. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2016, 60, 677-685.	0.9	7
122	Curing Operable Stage I Non-Small Cell Lung Cancer With Stereotactic Ablative Body Radiotherapy: The Force Awakens. <i>Oncologist</i> , 2016, 21, 393-398.	1.9	12
123	Defining the role of radiofrequency ablation and stereotactic ablative radiotherapy in patients with high-risk, early-stage non-small cell lung cancer. <i>Cancer</i> , 2016, 122, 322-323.	2.0	2
124	Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: Establishing a dose-response relationship. <i>Radiotherapy and Oncology</i> , 2016, 118, 540-546.	0.3	60
125	Practical Assessment of Bronchoscopically Inserted Fiducial Markers for Image Guidance in Stereotactic Lung Radiotherapy. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1363-1368.	0.5	11
126	Stereotactic ablative body radiotherapy for primary kidney cancer: what have we learned from prospective trials and what does the future hold?. <i>Future Oncology</i> , 2016, 12, 601-606.	1.1	6

#	ARTICLE	IF	CITATIONS
127	Systematic Endobronchial Ultrasound-guided Mediastinal Staging Versus Positron Emission Tomography for Comprehensive Mediastinal Staging in NSCLC Before Radical Radiotherapy of Non-small Cell Lung Cancer. <i>Medicine (United States)</i> , 2016, 95, e2488.	0.4	32
128	Australia and New Zealand Faculty of Radiation Oncology Lung Interest Cooperative: 2015 consensus guidelines for the use of advanced technologies in the radiation therapy treatment of locally advanced non-small cell lung cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2016, 60, 686-692.	0.9	1
129	Radiotherapy for Non-Small Cell Lung Cancer Induces DNA Damage Response in Both Irradiated and Out-of-field Normal Tissues. <i>Clinical Cancer Research</i> , 2016, 22, 4817-4826.	3.2	57
130	A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II). <i>BMC Cancer</i> , 2016, 16, 183.	1.1	34
131	Ga-68 MAA Perfusion 4D-PET/CT Scanning Allows for Functional Lung Avoidance Using Conformal Radiation Therapy Planning. <i>Technology in Cancer Research and Treatment</i> , 2016, 15, 114-121.	0.8	33
132	Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma. <i>Future Oncology</i> , 2016, 12, 637-645.	1.1	56
133	The Importance of Quasi-4D Path-Integrated Dose Accumulation for More Accurate Risk Estimation in Stereotactic Liver Radiotherapy. <i>Technology in Cancer Research and Treatment</i> , 2016, 15, 428-436.	0.8	2
134	Guidelines for safe practice of stereotactic body (ablative) radiation therapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2015, 59, 646-653.	0.9	37
135	Dosimetric Consequences of 3D Versus 4D PET/CT for Target Delineation of Lung Stereotactic Radiotherapy. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1112-1115.	0.5	9
136	Estimating lung ventilation directly from 4D CT Hounsfield unit values. <i>Medical Physics</i> , 2015, 43, 33-43.	1.6	42
137	Complications from Stereotactic Body Radiotherapy for Lung Cancer. <i>Cancers</i> , 2015, 7, 981-1004.	1.7	81
138	The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. <i>Cancer Treatment Reviews</i> , 2015, 41, 503-510.	3.4	482
139	Respiratory-gated (4D) FDG-PET detects tumour and normal lung response after stereotactic radiotherapy for pulmonary metastases. <i>Acta Oncologica</i> , 2015, 54, 1105-1112.	0.8	14
140	⁶⁸ Ga-EDTA PET/CT Imaging and Plasma Clearance for Glomerular Filtration Rate Quantification: Comparison to Conventional ⁵¹ Cr-EDTA. <i>Journal of Nuclear Medicine</i> , 2015, 56, 405-409.	2.8	32
141	A planning study investigating dual-gated volumetric arc stereotactic treatment of primary renal cell carcinoma. <i>Medical Dosimetry</i> , 2015, 40, 82-88.	0.4	1
142	Immunological markers that predict radiation toxicity. <i>Cancer Letters</i> , 2015, 368, 191-197.	3.2	50
143	High-resolution pulmonary ventilation and perfusion PET/CT allows for functionally adapted intensity modulated radiotherapy in lung cancer. <i>Radiotherapy and Oncology</i> , 2015, 115, 157-162.	0.3	83
144	The Use of Dual Vacuum Stabilization Device to Reduce Kidney Motion for Stereotactic Radiotherapy Planning. <i>Technology in Cancer Research and Treatment</i> , 2015, 14, 149-157.	0.8	15

#	ARTICLE	IF	CITATIONS
145	¹⁸F-FDG PET/CT perfusion imaging in response assessment of pulmonary metastases undergoing stereotactic ablative radiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2015, 59, 207-215.	0.9	7
146	The development of stereotactic body radiotherapy in the past decade: a global perspective. <i>Future Oncology</i> , 2015, 11, 2721-2733.	1.1	8
147	¹⁸ F-FDG PET/CT following chemoradiation of uterine cervix cancer provides powerful prognostic stratification independent of HPV status: a prospective cohort of 105 women with mature survival data. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1825-1832.	3.3	21
148	Accuracy and Utility of Deformable Image Registration in ⁶⁸ Ga 4D PET/CT Assessment of Pulmonary Perfusion Changes During and After Lung Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 196-204.	0.4	21
149	15-Year Experience of ¹⁸ F-FDG PET Imaging in Response Assessment and Restaging After Definitive Treatment of Merkel Cell Carcinoma. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1328-1333.	2.8	26
150	Correlation of ⁶⁸ Ga Ventilation-Perfusion PET/CT with Pulmonary Function Test Indices for Assessing Lung Function. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1718-1723.	2.8	29
151	Ventilation/Perfusion Positron Emission Tomography-Based Assessment of Radiation Injury to Lung. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 408-417.	0.4	41
152	Image guidance and stabilization for stereotactic ablative body radiation therapy (SABR) treatment of primary kidney cancer. <i>Practical Radiation Oncology</i> , 2015, 5, e597-e605.	1.1	7
153	Abscopal effects of radiation therapy: A clinical review for the radiobiologist. <i>Cancer Letters</i> , 2015, 356, 82-90.	3.2	354
154	Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: A systematic review. <i>Acta Oncologica</i> , 2015, 54, 148-157.	0.8	83
155	A Pattern of Early Radiation-Induced Inflammatory Cytokine Expression Is Associated with Lung Toxicity in Patients with Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2014, 9, e109560.	1.1	81
156	Short communication: timeline of radiation-induced kidney function loss after stereotactic ablative body radiotherapy of renal cell carcinoma as evaluated by serial ^{99m} Tc-DMSA SPECT/CT. <i>Radiation Oncology</i> , 2014, 9, 253.	1.2	26
157	Geographic miss of lung tumours due to respiratory motion: a comparison of 3D vs 4D PET/CT defined target volumes. <i>Radiation Oncology</i> , 2014, 9, 291.	1.2	34
158	A prospective observational study of Gallium-68 ventilation and perfusion PET/CT during and after radiotherapy in patients with non-small cell lung cancer. <i>BMC Cancer</i> , 2014, 14, 740.	1.1	26
159	Vacuum immobilisation reduces tumour excursion and minimises intrafraction error in a cohort study of stereotactic ablative body radiotherapy for pulmonary metastases. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014, 58, 244-252.	0.9	18
160	Stereotactic Ablative Body Radiation Therapy for Primary Kidney Cancer: A 3-Dimensional Conformal Technique Associated With Low Rates of Early Toxicity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 1061-1068.	0.4	58
161	Extracranial oligometastatic renal cell carcinoma: current management and future directions. <i>Future Oncology</i> , 2014, 10, 761-774.	1.1	27
162	Surgical and ablative therapies for the management of adrenal oligometastases: A systematic review. <i>Cancer Treatment Reviews</i> , 2014, 40, 838-846.	3.4	72

#	ARTICLE	IF	CITATIONS
163	Mobilization of Viable Tumor Cells Into the Circulation During Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 88, 395-403.	0.4	67
164	Conventional margins not sufficient for post-prostatectomy prostate bed coverage: An analysis of 477 cone-beam computed tomography scans. Radiotherapy and Oncology, 2014, 110, 235-239.	0.3	14
165	High-resolution imaging of pulmonary ventilation and perfusion with ⁶⁸ Ga-VQ respiratory gated (4-D) PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 343-349.	3.3	43
166	Results of patient specific quality assurance for patients undergoing stereotactic ablative radiotherapy for lung lesions. Australasian Physical and Engineering Sciences in Medicine, 2014, 37, 45-52.	1.4	9
167	Advances in local and ablative treatment of oligometastasis in prostate cancer. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 308-321.	0.7	18
168	Inflammation and Oxidative DNA Damage. , 2014, , 63-74.		2
169	Bronchoscopic Delivery of Lipiodol as a Fiducial Marker in Lung Tumors Before Radiotherapy. Journal of Thoracic Oncology, 2014, 9, 1579-1583.	0.5	17
170	Ten-year results of quality assurance in radiotherapy chart round. BMC Health Services Research, 2013, 13, 148.	0.9	12
171	Validation of a 4D-PET Maximum Intensity Projection for Delineation of an Internal Target Volume. International Journal of Radiation Oncology Biology Physics, 2013, 86, 749-754.	0.4	36
172	Effect of different breathing patterns in the same patient on stereotactic ablative body radiotherapy dosimetry for primary renal cell carcinoma: A case study. Medical Dosimetry, 2013, 38, 304-308.	0.4	9
173	¹⁸ F-FDG PET Provides High-Impact and Powerful Prognostic Stratification in the Staging of Merkel Cell Carcinoma: A 15-Year Institutional Experience. Journal of Nuclear Medicine, 2013, 54, 1223-1229.	2.8	84
174	Validating and improving CT ventilation imaging by correlating with ventilation 4D-PET/CT using ⁶⁸ Ga-labeled nanoparticles. Medical Physics, 2013, 41, 011910.	1.6	79
175	Abscopal Effects after Conventional and Stereotactic Lung Irradiation of Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, e71-e72.	0.5	78
176	An analysis of respiratory induced kidney motion on four-dimensional computed tomography and its implications for stereotactic kidney radiotherapy. Radiation Oncology, 2013, 8, 248.	1.2	43
177	A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma. BJU International, 2012, 110, E737-43.	1.3	108
178	Analysis of the impact of chest wall constraints on eligibility for a randomized trial of stereotactic body radiotherapy of peripheral stage non-small cell lung cancer. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 654-660.	0.9	3
179	Implementation of a lung radiosurgery program: Technical considerations and quality assurance in an Australian institution. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 354-361.	0.9	16
180	Impact of post-therapy positron emission tomography on prognostic stratification and surveillance after chemoradiotherapy for cervical cancer. Cancer, 2011, 117, 3981-3988.	2.0	57

#	ARTICLE	IF	CITATIONS
181	Stereotactic Radiotherapy for Pulmonary Oligometastases: A Systematic Review. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1091-1099.	0.5	206
182	Paraneoplastic encephalomyelitis associated with motor neuron disease causing respiratory failure in the setting of occult small cell lung carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008, 4, 118-121.	0.7	0